[The use of eiconol in the combined treatment of lichen ruber planus of the oral mucosa].
Clinical and laboratory examinations of patients with lichen ruber planus revealed diseases of the hepatobiliary system in 85%, pancreatic diseases in 29%, chronic gastritis with manifest secretory insufficiency in 32.5%, and fatty hepatosis in 17.5% of patients. Biochemical analysis of the peripheral blood in patients with the exudative hyperemic and erosive ulcerative forms of the disease revealed hypercholesterolemia and hypertriglyceridemia. Administration of eikonol in a dose of 6 g/day led to reduction of triglyceride level by 18% and of total cholesterol by 6%, the hypocholesterolemic and hypotriglyceridemic effect of the drug being more expressed in the patients with initially higher levels of these parameters. Eikonol therapy promoted an improvement in the clinical course of lichen planus. A positive time course of changes was observed in 69% of patients with the exudative hyperemic form of the disease (less expressed unpleasant subjective sensations, decrease of hyperemia of the buccal mucosa and of the size of foci of lesions, less pronounced papular pattern). In the group with the erosive ulcerative form of the disease only 18% of patients developed positive changes under the effect of therapy (epithelialization of erosions, attenuation of the inflammatory reaction, less expressed papular pattern). Combination of eikonol with applications of keratoplasties to the foci of lesions in patients with the erosive ulcerative condition brought about a better therapeutic effect, with the periods of epithelialization reducing by 7 to 10 days.